Healthcare provider profile · identity verified

Camille Ryan, MD

Family Practice · ROCKFORD, MI · NPI 1306250543

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	347	100
Lisinopril	Lisinopril	249	82
Levothyroxine Sodium	Levothyroxine Sodium	219	62
Omeprazole	Omeprazole	202	67
Hydrochlorothiazide	Hydrochlorothiazide	174	55
Amlodipine Besylate	Amlodipine Besylate	162	48
Losartan Potassium	Losartan Potassium	144	45
Rosuvastatin Calcium	Rosuvastatin Calcium	121	38
Metoprolol Succinate	Metoprolol Succinate	118	36
Trazodone Hcl	Trazodone Hcl	111	35
Sertraline Hcl	Sertraline Hcl	78	24
Mounjaro	Tirzepatide	75	19
Gabapentin	Gabapentin	70	29
Metformin Hcl	Metformin Hcl	70	22
Montelukast Sodium	Montelukast Sodium	68	25
Simvastatin	Simvastatin	63	21
Ozempic	Semaglutide	60	13
Pantoprazole Sodium	Pantoprazole Sodium	60	20
Bupropion Xl	Bupropion Hcl	55	20
Metformin Hcl Er	Metformin Hcl	54	20
Duloxetine Hcl	Duloxetine Hcl	53	20
Fluticasone Propionate	Fluticasone Propionate	49	22
Venlafaxine Hcl Er	Venlafaxine Hcl	49	14
Tamsulosin Hcl	Tamsulosin Hcl	48	16
Albuterol Sulfate Hfa	Albuterol Sulfate	46	32
Fluoxetine Hcl	Fluoxetine Hcl	44	11
Metoprolol Tartrate	Metoprolol Tartrate	44	16
Buspirone Hcl	Buspirone Hcl	40	13
Potassium Chloride	Potassium Chloride	40	15
Jardiance	Empagliflozin	37	13
Alendronate Sodium	Alendronate Sodium	34	11
Allopurinol	Allopurinol	33	suppressed
Citalopram Hbr	Citalopram Hydrobromide	32	suppressed
Furosemide	Furosemide	31	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	31	suppressed
Pravastatin Sodium	Pravastatin Sodium	31	12
Atenolol	Atenolol	28	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	27	suppressed
Lovastatin	Lovastatin	27	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	26	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	26	11
Tramadol Hcl	Tramadol Hcl	25	11
Amitriptyline Hcl	Amitriptyline Hcl	23	suppressed
Meloxicam	Meloxicam	22	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	22	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	22	19
Escitalopram Oxalate	Escitalopram Oxalate	21	suppressed
Alprazolam	Alprazolam	20	12
Carvedilol	Carvedilol	20	suppressed
Chlorthalidone	Chlorthalidone	20	suppressed
Primidone	Primidone	20	suppressed
Ibuprofen	Ibuprofen	19	suppressed
Ropinirole Hcl	Ropinirole Hcl	19	suppressed
Prednisone	Prednisone	18	16
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	12
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Methocarbamol	Methocarbamol	16	15
Valacyclovir	Valacyclovir Hcl	16	suppressed
Benazepril Hcl	Benazepril Hcl	15	suppressed
Famotidine	Famotidine	15	suppressed
Myrbetriq	Mirabegron	15	suppressed
Eliquis	Apixaban	14	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	14	suppressed
Ipratropium Bromide	Ipratropium Bromide	14	suppressed
Januvia	Sitagliptin Phosphate	14	suppressed
Lorazepam	Lorazepam	14	suppressed
Ramipril	Ramipril	14	suppressed
Finasteride	Finasteride	13	suppressed
Warfarin Sodium	Warfarin Sodium	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Glimepiride	Glimepiride	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	11
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Cephalexin	Cephalexin	11	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Solifenacin Succinate	Solifenacin Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error